On Demand Workshop: The Role of Psychotherapy in Psychedelic Treatment: What We Know and What the Future Might Hold

This presentation was originally reviewed on November 30, 2022, and broadcast live online on November 16, 2022, from 1:00 PM – 4:15 PM ET. 

The views and opinions expressed by this presenter in this lecture are their own, and do not represent the views of Sheppard Pratt.

Psychedelic therapy is re-emerging in the psychological field as a promising treatment for some mental disorders.  This program will review the current literature and outcomes of psychedelic research, as well as provide a general overview of the psychedelic treatment model.   At the completion of this program, participants should be able to identify the three phases of psychedelic therapy, the role of the therapist, and hypnotized psychological mechanisms of change in treatment responders.    

Target Audience

This activity is intended for psychologists, social workers, counselors, and other mental health professionals.

Learning Objectives

After this lecture, registrants will be able to:

  1. Identify 3 of the current mental health disorders being study using psilocybin.
  2. Discuss the 3 main phases of the psychedelic treatment.
  3. Define at least 1 unique element of psychedelic.
Course summary
Available credit: 
  • 3.00 ACEP NBCC clock hours
  • 3.00 Category II credits for Social Workers
  • 3.00 Psychologists
  • 3.00 Participation
Course opens: 
12/17/2022
Course expires: 
12/14/2024

There is no commercial support for this activity.

About The Speaker

Tammy Miller is a clinical psychologist that works full time in the Sheppard Pratt research department.  She is the lead psychotherapist for the psilocybin research trials being conducted at Sheppard Pratt. She is also a mentor and trainer for other psilocybin therapists.  Tammy has prior experience working in crisis work, outpatient community health,  inpatient hospitals, and private practice.  Tammy knew that she wanted to make meaningful contributions to society and discovered her passion in working in mental health and helping others.   When not working you can find Tammy spending time with her family, listening to music, and traveling.    

Stephanie Peck is a clinical psychologist and Associate Clinical Professor at the UC San Diego School of Medicine. She is co-investigator on two FDA-approved  trials evaluating psilocybin for eating disorders and acted as lead psychologist on a Phase 2b FDA approved trial evaluating psilocybin for treatment resistant depression. She has extensive experience delivering both psilocybin therapy and ketamine-assisted therapy. For the past 3.5 years, Stephanie has delivered psychedelic treatment in academic clinical research settings. She also serves as a therapist trainer and mentor to therapists delivering psilocybin therapy through clinical research trials.  Dr. Peck is a consultant for Compass Pathways, the life sciences company involved in bringing psychedelic treatment to market. She is a subject matter expert and has served as a content developer for the treatment and therapist training program for upcoming clinical trials. In addition to her work in psychedelics, Dr. Peck directs a treatment program for adolescents and adults at the UCSD Eating Disorders Treatment Center and is involved with program development. 

Nadav (Liam) Modlin is the Psychology & Psychotherapy Lead in Psychedelics at the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King's College London. With an interest in psychopharmacology and clinical expertise in treating psychological trauma, at the IoPPN Liam works as a research therapist, therapist trainer, and clinical investigator on studies exploring the safety and efficacy of psychedelics. As part of his doctoral studies, Liam conducts trauma-focused qualitative research investigating patients’ perspectives around traumatic stress symptoms, and experience of currently available and experimental treatments. His lectures at the IoPPN explore psychotherapeutic models in clinical trials investigating the safety and efficacy of psychedelics, the potential applications of psychedelic therapy in military populations and psychotherapy in affective disorders. He is also the co-founder of the Maudsley Psychedelic Society Harm Reduction 'Integration' Group. Based in London, Liam has a private counselling & psychotherapy practice and has worked in various NHS mental health services delivering psychodynamic psychotherapy and as a team lead.

Disclosure Statements

Sheppard Pratt holds the standard that its continuing medical education programs should be free of commercial bias and conflict of interest. In accord with Sheppard Pratt's Disclosure Policy, as well as standards of the Accreditation Council for Continuing Medical Education (ACCME) and the American Medical Association (AMA), all planners, reviewers, speakers and persons in control of content have been asked to disclose any relationship he /she has with any entity producing, marketing, selling, re-selling, or distributing health care goods or services consumed by, or used on, patients, during the past 24 months. All planners, reviewers and speakers have also been asked to disclose any payments accepted for this lecture from any entity besides Sheppard Pratt, and if there will be discussion of any products, services or off-label uses of product(s) during this presentation.

Tammy M. Miller, PsyD, reports that she is a consultant Compass Pathways. She will discuss the off-label use of psilocybin in this presentation. This speaker will be only discussing research findings, discovery, and modalities in this presentation. No specific products or services will be discussed. All conflicts have been mitigated through review. 

Stephanie Knatz Peck, PhD reports that she is a consultant and subject matter expert for Compass Pathways. She will discuss the off-label use of psilocybin in this presentation.  This speaker will be only discussing research findings, discovery, and modalities in this presentation. No specific products or services will be discussed. All conflicts have been mitigated through review. 

Nadav Modlin, MSc, MBACP,  reports that he is a consultant for Compass Pathways, Small Pharma, and Psytech. He will discuss the off-label use of psilocybin in this presentation. This speaker will be only discussing research findings, discovery, and modalities in this presentation. No specific products or services will be discussed. All conflicts have been mitigated through review. 

Event Planners/Reviewers Disclosures: The following event planners and/or reviewers are reported as having no financial interest, arrangement or affiliation with any entity producing, marketing, selling, re-selling, or distributing health care goods or services consumed by, or used on, patients, during the past 24 months: Todd Peters, MD, Deepak Prabhakar, MD, Elizabeth Ryznar, MD, MSc., Louis Marino, MD, Ehsan Syed, MD, Devi Bhuyan, PsyD, Faith Dickerson, PhD, Carrie Etheridge, LCSW-C, Tom Flis, LCPC, Laura Webb, RN-BC, MSN, Stacey Garnett, RN, MSN, Heather Billings, RN, Octavia Coit, MN, Lisa Illum MLIS, MEd, and Jennifer Tornabene.

Psychologist Statement: Sheppard Pratt is authorized by the State Board of Examiners of Psychologists as a sponsor of continuing education. Sheppard Pratt takes responsibility for the content, quality, and scientific integrity of this continuing education activity.  Sheppard Pratt designates this educational activity for a maximum of 3.0 contact hours for Psychologists.

Social Worker Statement: Sheppard Pratt is authorized by the Board of Social Work Examiners of Maryland to offer continuing education for Social Workers.  Sheppard Pratt takes responsibility for the content, quality, and scientific integrity of this continuing education activity. This activity is approved for 3.0 contact hours in Category II credits for Social Workers.

Counselor Statement:  Sheppard Pratt has been approved by NBCC as an Approved Continuing Education Provider, ACEP No. 5098.  Programs that do not qualify for NBCC credit are clearly identified.  Sheppard Pratt is solely responsible for all aspects of the program.  This activity is available for 3.0 NBCC clock hours.

Available Credit

  • 3.00 ACEP NBCC clock hours
  • 3.00 Category II credits for Social Workers
  • 3.00 Psychologists
  • 3.00 Participation
Please login or register to take this course.

ON DEMAND WEBINAR: FOR BEST RESULTS WATCH USING GOOGLE CHROME

Professional Workshop Series: The Role of Psychotherapy in Psychedelic Treatment: What We Know and What the Future Might Hold

Tammy M. Miller, PsyD

Licensed Clinical Psychologist

Sheppard Pratt

Baltimore, MD

Stephanie Knatz Peck, PhD

Licensed Clinical Psychologist

Associate Clinical Professor

UC San Diego School of Medicine

San Diego, CA

Nadav Modlin, MSc, MBACP

Psychology and Psychotherapy Lead in Psychedelics

Institute of Psychiatry, Psychology & Neuroscience 

King's College London

London, England

Originally reviewed November 30, 2022.
Originally broadcast live November 18, 2022, from 1:00 PM – 4:15 PM ET
Enduring Activity Credit Expiration Date: December 14, 2024

Activity Time: Three-hour webinar lecture with a 15-minute evaluation process. Total Time: 3:45

TO EARN CONTINUING EDUCATION CREDIT FOR YOUR ATTENDANCE
On the OVERVIEW or REGISTER/TAKE COURSE tab, select the GREEN RECTANGLE, TAKE COURSE to begin.
Select NEXT in the bottom right corner of the screen. Use the NEXT button for best results.
The PowerPoint handout will be available for download.
After downloading the handout, select NEXT to begin and watch the ninety-minute video. 
You may need to select play for the video to begin.
After the video follow the prompts to complete the evaluation and attestation of credit. 
Once you have completed all the components of the Course Progress bar, the certificate will be immediately downloadable.

FINANCIAL SUPPORT
There is no commercial support for this activity.

Questions? Look at our FAQ’s at https://cme.sheppardpratt.org/content/faq or Email cme@sheppardpratt.org

 

 

Required Hardware/software

Optimal System Configuration

Flash Player: Adobe Flash Player 10.1+

Browser: Firefox 3+, Internet Explorer 8.0+, Safari 4.0+, or Google Chrome 7.0+

Operating System: Windows XP+ or Mac OS X 10.4+

Internet Connection: 1 Mbps or higher

Minimum Requirements

Windows PC: 500-MHz Pentium II; Windows XP or higher; 128 MB RAM; Video Card at least 64MB of video memory; Sound Card at least 16-bit; Macromedia Flash Player 10 or higher, audio playback with speakers for programs with video content; Firefox 1.1+, Internet Explorer 7.0+, Safari 1.0+, Google Chrome, or Opera

Macintosh: Mac OS X 10.3 or higher with latest updates installed; 1.83MHz Intel Core Duo or faster; RAM: 128MB or more; Video Card: at least 64MB of video memory; Sound Card: at least 16-bit

Hardware/Software Specifications

This internet-based CME activity is best experienced using Internet Explorer 8+, Mozilla Firefox 3+, Safari 4+. This Web site requires that JavaScript and session cookies be enabled. Certain activities may require additional software to view multimedia, presentation, or printable versions of the content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Adobe Acrobat, Microsoft PowerPoint, and Windows Media Player.